Pruritus treatment Livmarli should be reimbursable: Canadian panel
A Canadian Agency for Drugs and Technologies in Health (CADTH) committee has recommended that Livmarli (maralixibat) be covered by the country’s publicly funded health…
A Canadian Agency for Drugs and Technologies in Health (CADTH) committee has recommended that Livmarli (maralixibat) be covered by the country’s publicly funded health…
The U.S. Food and Drug Administration (FDA) has again expanded its approval of Gilead Sciences’ medication Vemlidy (tenofovir alafenamide) for chronic hepatitis B…
The Phase 3 trial that supported the U.S. approval of Livmarli (maralixibat) for progressive familial intrahepatic cholestasis (PFIC) involved the broadest range of patients,…
Blood vessel abnormalities in the brain, such as unusually narrow or bulging vessels, are common in children with Alagille syndrome and remain generally stable over…
The U.S. Food and Drug Administration (FDA) agreed to review an application seeking full and formal approval of Ocaliva (obeticholic acid) as a…
The U.S. Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals’ Livmarli (maralixibat) to reduce pruritus, or itching, in adults and children, 5 years…
Women with intrahepatic cholestasis of pregnancy (ICP) show lesser diversity across their gut bacteria than do other pregnant women, a study reports. Its findings…
Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…